RVMD Stock Cash Flow Statements

Revolution Medicines Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Revolution Medicines Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31

cash flows from operating activities
net income	-247,787,000	-213,416,000	-194,569,000	-156,288,000	-133,233,000	-116,003,000	-161,537,000	-108,434,000	-98,298,000	-68,098,000	-56,507,000	-73,329,000	-61,222,000	-57,647,000	-52,676,000	-52,940,000	-44,299,000	-37,176,000	-34,204,000	-27,221,000	-27,215,000	-19,519,000
adjustments to reconcile net income to net cash from operating activities:
loss on disposal of fixed assets			-200,000	202,000	43,000	73,000	51,000	0	0	1,000	0			19,000
amortization of intangible assets	267,000	267,000	267,000	268,000	267,000	267,000	267,000	267,000	267,000	267,000	268,000	267,000	267,000	267,000	267,000	267,000	268,000	267,000	267,000	267,000	267,000	267,000
stock-based compensation expense	28,830,000	25,084,000	22,439,000	20,775,000	19,775,000	16,208,000	25,427,000	13,666,000	12,980,000	9,699,000	8,316,000	8,138,000	8,098,000	6,644,000	6,197,000	5,827,000	5,313,000	3,387,000	2,632,000	2,670,000	2,017,000	1,567,000
depreciation and amortization	1,758,000	1,692,000							1,223,000	1,205,000	1,149,000	991,000	931,000	901,000	816,000	793,000	803,000	671,000	674,000	665,000	640,000	632,000
change in fair value of warrant liabilities and contingent earn-out shares	4,578,000	-2,439,000		1,269,000	-1,907,000	-3,905,000
non-cash interest expense on liability related to sale of future royalties
net amortization of premium or discount on marketable securities	-7,743,000	-9,817,000	-8,826,000	-9,593,000	-10,902,000	-15,244,000	-8,633,000	-5,144,000	-4,851,000	-3,577,000
amortization of operating lease right-of-use asset	1,777,000	1,757,000	1,385,000	967,000	888,000	956,000	1,244,000	611,000	283,000	1,061,000	1,182,000	1,175,000	1,136,000	1,122,000	979,000	691,000	770,000	740,000	759,000	698,000	764,000	645,000
impairment of assets				0	0	2,761,000
changes in operating assets and liabilities:
accounts receivable			0	0	0	1,254,000	-945,000	2,201,000	1,485,000	678,000	267,000	684,000	-241,000	546,000		-885,000	1,037,000	-1,171,000
prepaid expenses and other current assets	-7,361,000	6,426,000	-5,112,000	4,357,000	-8,353,000	-590,000	-2,252,000	-870,000	-1,135,000	1,611,000	4,586,000	834,000	-5,783,000	-3,416,000	638,000	694,000	123,000	-1,257,000	158,000	459,000	661,000	-3,202,000
accounts payable	8,761,000	-8,270,000	29,363,000	-2,788,000	-4,080,000	-28,960,000	24,305,000	580,000	8,634,000	-1,050,000	-1,507,000	10,239,000	-952,000	-492,000	2,573,000	189,000	1,608,000	-2,131,000	4,616,000	-3,370,000	2,143,000	-3,084,000
accrued expenses and other current liabilities	10,820,000	1,549,000	18,298,000	10,281,000	14,665,000	-21,259,000	-6,291,000	7,577,000	15,134,000	-1,752,000	-2,966,000	-1,295,000	7,877,000	-2,114,000	3,743,000	1,734,000	2,043,000	1,200,000	-191,000	3,760,000	2,249,000	-963,000
operating lease liability	-1,555,000	-1,501,000	993,000	-705,000	-618,000	85,000	-175,000	-408,000	-55,000	-894,000	-995,000	248,000	-962,000	-719,000	-590,000	-706,000	498,000	-670,000	-650,000	-642,000	-498,000	-775,000
other noncurrent assets	-17,273,000	765,000	8,000	-1,881,000	-4,127,000	125,000	7,081,000	-8,673,000	88,000	90,000	-2,051,000	-153,000	71,000	-114,000					-266,000	131,000
other noncurrent liabilities	2,305,000	3,468,000	-768,000	1,075,000	-2,227,000	2,132,000	-524,000	730,000	-1,442,000	1,393,000	-170,000	340,000	-1,391,000	1,031,000	-271,000	366,000	-797,000	853,000	-390,000	439,000	146,000	-19,000
net cash from operating activities	-221,757,000	-194,435,000	-138,290,000	-130,419,000	-128,167,000	-160,560,000	-120,563,000	-100,497,000	-67,121,000	-62,391,000	-61,788,000	-51,737,000	-55,716,000	-55,160,000	-39,265,000	-36,588,000	-34,081,000	-37,246,000	-25,034,000	-27,021,000	-19,991,000	-28,018,000
capex	-7,328,000	-481,000	-262,000	-5,666,000	-1,526,000	-1,278,000	-1,035,000	-3,236,000	167,000	-1,014,000	-4,211,000	-3,701,000	-1,268,000	-217,000	-98,000	-648,000	-1,956,000	-2,697,000	203,000	-776,000	19,000	-566,000
free cash flows	-229,085,000	-194,916,000	-138,552,000	-136,085,000	-129,693,000	-161,838,000	-121,598,000	-103,733,000	-66,954,000	-63,405,000	-65,999,000	-55,438,000	-56,984,000	-55,377,000	-39,363,000	-37,236,000	-36,037,000	-39,943,000	-24,831,000	-27,797,000	-19,972,000	-28,584,000
cash flows from investing activities
purchases of marketable securities	-529,291,000	-510,036,000	-695,210,000	-364,877,000	-374,855,000	-701,681,000	-519,605,000	-170,039,000	-176,175,000	-193,097,000	-160,335,000	-212,964,000	-127,652,000	-111,818,000	-110,814,000	-168,248,000	-278,235,000	-114,038,000	-44,876,000	-194,052,000	-205,167,000	-100,038,000
maturities of marketable securities	564,633,000	497,353,000	303,529,000	346,928,000	485,198,000	456,882,000	141,520,000	249,926,000	133,750,000	198,851,000	156,107,000	93,051,000	192,579,000	157,732,000	120,530,000	129,533,000	156,765,000	119,926,000	108,991,000	93,772,000	66,140,000	40,925,000
sales of marketable securities															0				0	0
purchases of property and equipment	-7,450,000	-3,266,000	-1,222,000	-3,520,000	-2,399,000	-3,167,000	-2,317,000	-2,535,000	-1,119,000	-1,758,000	-2,876,000	-3,525,000	-2,526,000	-1,889,000	-1,183,000	-454,000	-1,312,000	-3,579,000	-1,169,000	-687,000	-474,000	-603,000
net cash from investing activities	34,276,000	-15,949,000	-392,903,000	-21,469,000	107,944,000	-247,966,000	-380,402,000	77,352,000	-43,544,000	3,996,000	-7,104,000	-123,438,000	62,401,000	44,025,000	8,533,000	-30,177,000	-122,782,000	2,309,000	62,946,000	-100,967,000	-136,496,000	-59,716,000
cash flows from financing activities
proceeds from issuance of common stock under equity incentive plans	1,937,000	891,000	4,179,000	3,001,000	4,340,000	810,000	1,338,000	1,011,000	468,000	499,000	777,000	209,000	190,000	305,000	356,000	319,000	257,000	555,000	687,000	1,077,000	86,000	27,000
proceeds from issuance of common stock related to employee stock purchase plan			1,865,000	0			1,208,000	0			625,000	0				0
proceeds from the sale of future royalties
exercise of warrants	0	1,000
deferred offering costs	2,000	-18,000
net cash from financing activities	256,583,000	874,000	873,805,000	77,294,000	7,504,000	810,000	839,354,000	1,011,000	64,630,000	324,205,000	51,363,000	248,335,000	1,429,000	305,000	10,728,000	319,000	868,000	282,264,000	1,485,000	168,883,000	-1,336,000	253,744,000
net decrease in cash, cash equivalents and restricted cash	69,102,000	-209,510,000
cash, cash equivalents and restricted cash - beginning of period	0	546,762,000		0	0	699,179,000		0	0	163,149,000		0	0	110,234,000		0	0	105,352,000
cash, cash equivalents and restricted cash - end of period	69,102,000	337,252,000	342,612,000	-74,594,000	-12,719,000	291,463,000	338,389,000	-22,134,000	-46,035,000	428,959,000	-17,529,000	73,160,000	8,114,000	99,404,000		-66,446,000	-155,995,000	352,679,000		40,895,000
reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets
cash and cash equivalents	68,884,000	333,554,000	341,802,000	-74,451,000	-12,719,000	288,432,000	337,749,000	-21,931,000	-46,892,000	427,222,000	-17,529,000	73,160,000	8,114,000	97,667,000	-20,657,000	-66,446,000	-155,995,000	351,595,000	39,397,000	40,895,000	-158,693,000	182,669,000
restricted cash	218,000	3,698,000	810,000	-143,000	0	3,031,000	640,000	-203,000	857,000	1,737,000	0	0	0	1,737,000	653,000	0	0	1,084,000	0	0	870,000	214,000
supplemental disclosure of non-cash investing and financing activities
purchases of property and equipment in accounts payable and accrued expenses and other current liabilities	122,000	2,785,000	960,000	-2,146,000	873,000	1,889,000	1,282,000	-701,000	1,286,000	744,000	-1,335,000	-176,000	1,258,000	1,672,000	1,085,000	-194,000	-644,000	882,000	1,372,000	-89,000	493,000	37,000
unpaid issuance costs on the liability related to the sale of future royalties
change in fair value of warrant liability and contingent earn-out shares
deferred revenue							0	0	-1,434,000	-3,025,000	-10,645,000	1,581,000	-3,572,000	-1,836,000	-3,412,000	6,385,000	-2,141,000	-2,493,000
deferred tax liability							-43,000				-123,000								359,000	0	-18,000	-716,000
cash, cash equivalents and restricted cash acquired in connection with eqrx acquisition, net of transaction costs
proceeds from issuance of common stock, net of issuance costs											0				0	0	-564,000	281,709,000	-34,000
proceeds from issuance of pre-funded warrants, net of transaction costs
proceeds from issuance of common stock from at-the-market offering, net of transaction costs
tax payment for common stock withheld in satisfaction of withholding tax requirements
payments of deferred offering costs
net increase in cash, cash equivalents and restricted cash			342,612,000	-74,594,000	-12,719,000	-407,716,000	338,389,000	-22,134,000	-46,035,000	265,810,000	-17,529,000	73,160,000			-20,004,000	-66,446,000	-155,995,000	247,327,000	39,397,000	40,895,000	-157,823,000	166,010,000
cash, cash equivalents and restricted cash - beginning of year																					0	16,873,000
cash, cash equivalents and restricted cash - end of year																					-157,823,000	182,883,000
issuance of common stock for eqrx acquisition
fair value of net assets acquired in connection with eqrx acquisition
right-of-use assets obtained in exchange for operating lease liabilities										286,000									0	0
depreciation				1,642,000	1,642,000	1,540,000	1,347,000
proceeds from issuance of common stock upon follow-on offering, net of issuance costs								0	0	323,706,000
proceeds from issuance of common stock upon at-the-market offering, net of issuance costs								0
unpaid/deferred offering costs						15,000	-1,000	-11,000	7,000	7,000
eqrx acquisition transaction costs incurred but not paid
vesting of early exercised options and restricted stock											0	88,000	24,000	31,000	27,000	42,000	34,000	46,000	67,000	41,000	44,000	47,000
advance payments for property and equipment
net amortization of premium (discount) on marketable securities
proceeds from issuance of common stock from at-the-market offering
unpaid deferred offering costs													-72,000	89,000						-207,000
loss on disposal of fixed asset
net amortization of premium on marketable securities													27,000	648,000
net increase/(decrease) in cash, cash equivalents and restricted cash														-10,830,000
loss on disposal of property and equipment
loss on disposal of held for sale assets
net amortization (accretion) of premium (discount) on marketable securities																	693,000	534,000	586,000	400,000	87,000	-105,000
account receivable
deferred rent
proceeds from sales of property and equipment
proceeds from sale of held for sale assets
proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
proceeds from issuance of common stock under employee stock purchase plan
repurchases of early exercised stock options
cash, cash equivalents and restricted cash – beginning of year
cash, cash equivalents and restricted cash – end of year
repurchases of early exercised stock
unpaid offering costs																		564,000				1,417,000
change in fair value of redeemable convertible preferred stock liability
receivable from related party																			2,906,000	-1,968,000	1,119,000	287,000
deferred revenue, related party																			-2,290,000	-3,309,000	-2,627,000	-3,033,000
cash acquired in warp drive acquisition
redeemable convertible preferred stock issued in warp drive acquisition
extinguishment of redeemable convertible preferred stock liability
unpaid consideration for warp drive acquisition included within accrued expenses and other current liabilities
conversion of convertible note payable into series b redeemable convertible preferred stock
loss on disposal of held-for-sale assets
proceeds from sale of property and equipment
proceeds from sale of held-for-sale assets
gain on disposal of property and equipment
proceeds from issuance of common stock in initial public offering, net of issuance costs																					-1,417,000	253,717,000
unpaid series c redeemable convertible preferred stock issuance costs
purchases of property and equipment in accounts payable

We provide you with 20 years of cash flow statements for Revolution Medicines stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Revolution Medicines stock. Explore the full financial landscape of Revolution Medicines stock with our expertly curated income statements.

The information provided in this report about Revolution Medicines stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.